Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
November 05, 2021 07:30 ET
|
Immunovant
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Participate in Roivant R&D Day 2021
September 27, 2021 08:00 ET
|
Immunovant
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Appoints Renee Barnett as Chief Financial Officer
September 15, 2021 07:00 ET
|
Immunovant
Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 ...
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
August 09, 2021 06:30 ET
|
Immunovant
NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Report Financial Results for Quarter Ended June 30, 2021
August 06, 2021 16:22 ET
|
Immunovant
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
August 02, 2021 07:30 ET
|
Immunovant
Proceeds will fund continued development of IMVT-1401 in multiple indications NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company...
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021
June 01, 2021 07:31 ET
|
Immunovant
Immunovant plans to resume clinical development of IMVT-1401 in Myasthenia Gravis (MG) and Warm Autoimmune Hemolytic Anemia (WAIHA) as well as initiate two additional mid-to-late stage studies in the...
Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020
February 16, 2021 08:00 ET
|
Immunovant
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
February 02, 2021 06:30 ET
|
Immunovant
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update
January 12, 2021 17:00 ET
|
Immunovant
Dr. Jain brings deep expertise in the design and execution of complex clinical trials, having overseen the development of more than 15 new chemical entities and marketed productsDr. Jain’s broad and...